Communication
ChemComm
7 (a) D. J. Aitken, F. Capitta, A. Frongia, J. Ollivier, P. P. Piras and
F. Secci, Synlett, 2011, 712; (b) D. J. Aitken, F. Capitta, A. Frongia,
J. Ollivier, P. P. Piras and F. Secci, Synlett, 2012, 727.
8 (a) D. J. Aitken, P. Caboni, H. Eijsberg, A. Frongia, R. Guillot, J. Ollivier,
P. P. Piras and F. Secci, Adv. Synth. Catal., 2014, 356, 941; (b) A. Frongia,
N. Melis, I. Serra, F. Secci, P. P. Piras and P. Caboni, Asian J. Org. Chem.,
2014, 3, 378; (c) N. Melis, L. Ghisu, R. Guillot, P. Caboni, F. Secci,
D. J. Aitken and A. Frongia, Eur. J. Org. Chem., 2015, 4358.
9 L. Ghisu, N. Melis, F. Secci, P. Caboni and A. Frongia, Tetrahedron,
2016, 72, 8201.
10 (a) A. F. Vaquer, A. Frongia, F. Secci and E. Tuveri, RSC Adv., 2015,
5, 96695; (b) A. Luridiana, A. Frongia, D. J. Aitken, R. Guillot,
G. Sarais and F. Secci, Org. Biomol. Chem., 2016, 14, 3394.
11 (a) H. Stadler, Helv. Chim. Acta, 2015, 98, 1189; (b) B. B. Snider and
M. Walner, Tetrahedron, 1989, 45, 3171; (c) K. E. Harding,
J. B. Strickland and J. Pommerville, J. Org. Chem., 1988, 53, 4877;
(d) J. M. Conia and J. Salaun, Acc. Chem. Res., 1972, 5, 33.
12 (a) J. P. Barnier, J. M. Denis, J. Salaun and J. M. Conia, Tetrahedron,
1974, 30, 1397; (b) V. Ghembus, L. Karmazin, S. Pira and D. Uguen,
Bull. Chem. Soc. Jpn., 2018, 91, 319.
13 (a) B. M. Trost, W. C. Vladuchick and A. J. Bridges, J. Am. Chem. Soc.,
1980, 102, 3548; (b) B. M. Trost and L. Jungheim, J. Am. Chem. Soc.,
1980, 102, 7910.
Scheme 5 Formal synthesis of the anti-inflammatory BK-B1 receptor
antagonist, 11.
14 (a) T. Cohen, W. M. Daniewski and R. B. Weisenfeld, Tetrahedron
Lett., 1978, 47, 4665; (b) A. M. Bernard, A. Frongia, P. P. Piras,
F. Secci and M. Spiga, Org. Lett., 2005, 7, 4565.
To the best of our knowledge, there is no literature precedent for
this transformation; most known synthetic methods proceed via
pre-formed arylthiocyclopropane intermediates.11–13 The efficient
access to compound 10, the known precursor of a biologically
active compound, suggests that this synthetic methodology may be
of interest for the preparation of other multifunctional cyclopro-
pane derivatives as building blocks in medicinal chemistry.
15 (a) K. Tanaka, H. Uneme, S. Matsui, R. Tanikaga and A. Kaji, Chem.
Lett., 1980, 287; (b) A. M. Bernard, E. Cadoni, A. Frongia, P. P. Piras
and F. Secci, Org. Let., 2002, 4, 2565; (c) A. M. Bernard, A. Frongia,
R. Guillot, P. P. Piras, F. Secci and M. Spiga, Org. Lett., 2007, 9, 541.
16 Regarding the tendency of alkylthiols to produce of 2-
sulfanylcyclobutanones 5 (Scheme 2), we suppose that kinetic
effects and differences in the ability of alkyl and aryl sulfur deriva-
tives to stabilize a positive charge in cyclobutylthionium ions are
consequential in this transformation.
17 W. H. Urry and D. J. Trecker, J. Am. Chem. Soc., 1961, 84, 118.
18 18O-1a was prepared as described in the ESI.† Reaction of this
compound with thiophenol 2a (1.0 equiv.) in the presence of PTSA
(20 mol%) afforded the corresponding carbaldehyde 18O-3a in 92%
yield (18O incorporation 78%). See ESI† for details.
Conflicts of interest
19 L. A. Paquette and J. E. Hofferberth, The a-Hydroxy Ketone (a Ketol)
and Related Rearrangements, 2003, pp. 477–567.
There is no conflict of interest regarding this paper.
20 (a) H.-U. Reissig and R. Zimmer, Chem. Rev., 2003, 103, 1151; (b) J.-I.
Matsuo, Tetrahedron Lett., 2014, 55, 2589; (c) Y. A. Volkova, E. M.
Budynina, A. E. Kaplun, O. A. Ivanova, A. O. Chagarovskiy, D. A.
Skvortsov, V. B. Rybakov, I. V. Trushkov and M. Y. Melni-kov, Chem. –
Eur. J., 2013, 19, 6586; (d) O. A. Ivanova, E. M. Budynina, A. O.
Chagarovskiy, I. V. Trushkov and Y. Melnikov, J. Org. Chem., 2011,
76, 8852; (e) J.-I. Matsuo, S. Sasaki, T. Hoshikawa and H. Ishibashi, Org.
Lett., 2009, 17, 3822; ( f ) J.-I. Matsuo, R. Okado and H. Ishibashi, Org. Lett.,
2010, 12, 3266; (g) A. M. Bernard, A. Frongia, P. P. Piras, F. Secci and
M. Spiga, Org. Lett., 2005, 7, 4565; (h) G. Alberti, A. M. Bernard, C. Floris,
A. Frongia, P. P. Piras, F. Secci and M. Spiga, Org. Biomol. Chem., 2009,
7, 3512.
Notes and references
1 J. J. Bloomfield and J. M. Nelke, Org. Synth., 1988, 6, 167.
2 (a) J. C. Namsylo and D. E. Kaufmann, Chem. Rev., 2003, 103, 1485;
(b) E. Lee-Ruff and G. Mladenova, Chem. Rev., 2003, 103, 1449;
(c) E. Lee-Ruff, The Chemistry of Cyclobutanes, ed. Z. Rappoport and
J. F. Liebman, Wiley, Chichester, 2005, p. 281; (d) J. Salau¨n, Sci.
Synth., 2004, 26, 557; (e) F. Secci, A. Frongia and P. P. Piras,
Molecules, 2013, 18, 15541; ( f ) S. Chen, G. Shan, P. Nie and
Y. Rao, Asian J. Org. Chem., 2015, 4, 16.
3 M. Ohno, L. Oguri and E. Shoji, J. Org. Chem., 1992, 64, 8995.
4 R. W. Saalfrank, W. Hafner, J. Markmann, A. Welch, K. Peters, 21 Ring contraction of cyclobutanone 1e was carried out by using CSA
G. Hans and Z. Naturforsch, J. Chem. Sci., 1994, 49, 389.
5 S. Danappe, A. Pal, C. Alexandre, A. M. Aubertin, N. Bourgougnon
and F. Huet, Tetrahedron, 2005, 61, 5782.
6 (a) N. Melis, F. Secci, T. Boddaert, D. J. Aitken and A. Frongia, Chem.
Commun., 2015, 51, 15272; (b) A. Martis, A. Luridiana, A. Frongia,
(ee 4 99%) as a catalyst, yielding the corresponding cyclopropyl-
derivative trans-6e as a racemic mixture.
22 (a) For reviews on bradykinin receptors and therapeutic targets see:
J. Howl and S. J. Payne, Expert Opin. Ther. Targets, 2003, 7, 277;
´
(b) D. Regoli and J. Barabe, Pharmacol. Rev., 1980, 32, 1.
M. Arca, G. Sarais, D. J. Aitken, R. Guillot and F. Secci, Org. Biomol. 23 B. C. Askew, T. Aya, K. Biswas, J. J. Chen, H. J. Brooks and Q. Wenyuan,
Chem., 2017, 15, 10053.
Substituted sulfones and methods of use, WO 2006041888, 2006.
13550 | Chem. Commun., 2018, 54, 13547--13550
This journal is ©The Royal Society of Chemistry 2018